Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph J Zech

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
European Radiology|August 7, 2019
Consensus report from the 8th International Forum for Liver Magnetic Resonance ImagingChristoph J Zech, Ahmed Ba-Ssalamah, Thomas Berg, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 3, 2014
Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinomaFrank T Kolligs, Jose I Bilbao, Tobias Jakobs, et al.
European Radiology|September 1, 2021
Correlation of liver enhancement in gadoxetic acid-enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trialOsman Öcal, Bora Peynircioglu, Christian Loewe, et al.
Biomedicines|May 28, 2022
Extrahepatic Disease in Hepatocellular Carcinoma: Do We Always Need Whole-Body CT or Is Liver MRI Sufficient? A Subanalysis of the SORAMIC TrialThomas Geyer, Philipp M Kazmierczak, Ingo G Steffen, et al.
Journal of Magnetic Resonance Imaging : JMRI|January 26, 2010
Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumineAntonella Filippone, Anthony Blakeborough, Josy Breuer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 2, 2022
Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenibOsman Öcal, Kerstin Schütte, Christoph J Zech, et al.
Insights Into Imaging|August 31, 2019
Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR)Nandita M deSouza, Eric Achten, Angel Alberich-Bayarri, et al.
United European Gastroenterology Journal|July 15, 2024
Skeletal muscle quality predicts overall survival in advanced liver hepatocellular carcinoma treated with SIRT and sorafenib: A subanalysis of the SORAMIC trialAlexey Surov, Andreas Wienke, Jan Borggrefe, et al.
Gut|January 21, 2022
Stimulatory MAIT cell antigens reach the circulation and are efficiently metabolised and presented by human liver cellsMartin J Lett, Hema Mehta, Adrian Keogh, et al.
Digestive Diseases (Basel, Switzerland)|April 29, 2026
Bone mineral density does not predict overall survival in patients with advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trialMaximilian Thormann, Andreas Wienke, Ricarda Seidensticker, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
European Radiology|August 7, 2019
Consensus report from the 8th International Forum for Liver Magnetic Resonance ImagingChristoph J Zech, Ahmed Ba-Ssalamah, Thomas Berg, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 3, 2014
Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinomaFrank T Kolligs, Jose I Bilbao, Tobias Jakobs, et al.
European Radiology|September 1, 2021
Correlation of liver enhancement in gadoxetic acid-enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trialOsman Öcal, Bora Peynircioglu, Christian Loewe, et al.
Biomedicines|May 28, 2022
Extrahepatic Disease in Hepatocellular Carcinoma: Do We Always Need Whole-Body CT or Is Liver MRI Sufficient? A Subanalysis of the SORAMIC TrialThomas Geyer, Philipp M Kazmierczak, Ingo G Steffen, et al.
Journal of Magnetic Resonance Imaging : JMRI|January 26, 2010
Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumineAntonella Filippone, Anthony Blakeborough, Josy Breuer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 2, 2022
Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenibOsman Öcal, Kerstin Schütte, Christoph J Zech, et al.
Insights Into Imaging|August 31, 2019
Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR)Nandita M deSouza, Eric Achten, Angel Alberich-Bayarri, et al.
United European Gastroenterology Journal|July 15, 2024
Skeletal muscle quality predicts overall survival in advanced liver hepatocellular carcinoma treated with SIRT and sorafenib: A subanalysis of the SORAMIC trialAlexey Surov, Andreas Wienke, Jan Borggrefe, et al.
Gut|January 21, 2022
Stimulatory MAIT cell antigens reach the circulation and are efficiently metabolised and presented by human liver cellsMartin J Lett, Hema Mehta, Adrian Keogh, et al.
Digestive Diseases (Basel, Switzerland)|April 29, 2026
Bone mineral density does not predict overall survival in patients with advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trialMaximilian Thormann, Andreas Wienke, Ricarda Seidensticker, et al.
Pageof 8